preloader icon



Apex Trader Funding (ATF) - News

LENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital

SAN DIEGO, July 15, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (NASDAQ:LENZ), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that it has entered into a stock purchase agreement with Ridgeback Capital Investments L.P. ("Ridgeback Capital") for a $30 million private investment in public equity ("PIPE") common stock financing. "We appreciate the significant support and confidence that Ridgeback Capital is showing in LENZ and are pleased to have access to this additional capital, which further strengthens our Balance Sheet as we aim to make LNZ100 a potentially best-in-class therapeutic option for the treatment of presbyopia," said Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics. "With our strong Phase 3 CLARITY data in hand and impressed by the excitement from KOLs that studied LNZ100, we are looking forward to upcoming milestones, including the submission of our NDA for LNZ100 mid-year 2024 and turning our full focus towards preparing for the potential approval and commercialization of LNZ100".   "We invest in innovative people and companies that help patients. LENZ is developing a medicine that can have a transformational impact on eyesight. This can benefit millions of people who live with the challenges of presbyopia, and we are excited to support the LENZ team in this effort," said Dr. Wayne Holman, Chief Executive Officer and Founder ...